Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR

被引：0
|
作者：
Weisel, K. [1 ]
Palumbo, A. [2 ]
Chanan-Khan, A. [3 ]
Nooka, A. K. [4 ]
Spicka, I. [5 ]
Masszi, T. [6 ]
Beksac, M. [7 ]
Hungria, V. [8 ]
Munder, M. [9 ]
Mateos, M-V. [10 ]
Mark, T. M. [11 ]
Spencer, A. [12 ]
Qi, M. [13 ]
Schecter, J. [14 ]
Amin, H. [14 ]
Qin, X. [15 ]
Deraedt, W. [16 ]
Ahmadi, T. [13 ]
Sonneveld, P. [17 ]
机构：
[1] Eberhard Karls Univ Tubingen, Univ Klinikum Tuebingen, Dept Hematol Oncol Immunol Rheumatol & Pulmonol, Abt Innere Med 2, Tubingen, Germany
[2] Univ Turin, Dept Hematol, Turin, Italy
[3] Mayo Clin Florida, Div Hematol & Med Oncol, Jacksonville, FL USA
[4] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[5] Charles Univ Prague, Med Dept 1, Dept Clin Haematol, Prague, Czech Republic
[6] Semmelweis Univ, St Laszlo Hosp, Dept Haematol & Stem Cell Transplantat, Budapest, Hungary
[7] Ankara Univ, Dept Hematol, Ankara, Turkey
[8] Irmandade Santa Casa De Misericordia Sao Paulo, Sao Paulo, Brazil
[9] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 3, Mainz, Germany
[10] Univ Hosp Salamanca, IBSAL, Salamanca, Spain
[11] Weill Cornell Med Coll, New York, NY USA
[12] Monash Univ, Malignant Haematol & Stem Cell Transplantat Serv, Alfred Hlth, Melbourne, Vic, Australia
[13] Janssen Res & Dev LLC, Spring House, PA USA
[14] Janssen Res & Dev LLC, Raritan, NJ USA
[15] Janssen Res & Dev LLC, Horsham, PA USA
[16] Janssen Res & Dev, Beerse, Belgium
[17] Erasmus MC, Dept Hematol, Rotterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw375.1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
906O
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR).
    Lentzsch, Suzanne
    Weisel, Katja C.
    Mateos, Maria-Victoria
    Hungria, Vania
    Munder, Markus
    Nooka, Ajay K.
    Mark, Tomer
    Quach, Hang
    Scott, Emma Catherine
    Lee, Je-Jung
    Sonneveld, Pieter
    Casneuf, Tineke
    Chiu, Christopher
    Qin, Xiang
    Amin, Himal
    Thiyagarajah, Piruntha
    Schecter, Jordan Mark
    Qi, Ming
    Spencer, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.
    Palumbo, Antonio
    Chanan-Khan, Asher Alban Akmal
    Weisel, Katja
    Nooka, Ajay K.
    Masszi, Tamas
    Beksac, Meral
    Spicka, Ivan
    Hungria, Vania T. M.
    Mateos, Maria-Victoria
    Mark, Tomer Martin
    Qi, Ming
    Schecter, Jordan Mark
    Amin, Himal
    Qin, Xiang
    Deraedt, William
    Ahmadi, Tahamtan
    Spencer, Andrew
    Sonneveld, Pieter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)
  • [3] UPDATED EFFICACY AND SAFETY ANALYSIS OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (DVD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM; CASTOR)
    Mateos, M. M.
    Spencer, A.
    Hungria, V
    Nooka, A. K.
    Estell, J.
    Barreto, W.
    Corradini, P.
    Min, C. K.
    Medvedova, E.
    Thiyagarajah, P.
    Deraedt, W.
    Chiu, C.
    Schecter, J. M.
    Weisel, K.
    HAEMATOLOGICA, 2018, 103 : 30 - 30
  • [4] EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF CASTOR
    Weisel, K.
    Lentzsch, S.
    Mateos, M. V.
    Hungria, V.
    Munder, M.
    Nooka, A.
    Mark, T.
    Quach, H.
    Scott, E. C.
    Lee, J. -J.
    Sonneveld, P.
    Casneuf, T.
    Chiu, C.
    Qin, X.
    Amin, H.
    Thiyagarajah, P.
    Schecter, J. M.
    Qi, M.
    Spencer, A.
    HAEMATOLOGICA, 2017, 102 : 168 - 169
  • [5] Daratumumab, Bortezomib, and Dexamethasone (DVd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Castor
    Spencer, Andrew
    Hungria, Vania T. M.
    Mateos, Maria-Victoria
    Nooka, Ajay
    Estell, Jane
    Barreto, Wolney G.
    Corradini, Paolo
    Min, Chang-Ki
    Medvedova, Eva
    Thiyagarajah, Piruntha
    Deraedt, William
    Chiu, Christopher
    Schecter, Jordan
    Weisel, Katja C.
    BLOOD, 2017, 130
  • [6] PHASE 3 RANDOMISED CONTROLLED STUDY OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CASTOR
    Palumbo, A.
    Chanan-Khan, A.
    Weisel, K.
    Nooka, A. K.
    Masszi, T.
    Beksac, M.
    Spicka, I.
    Hungria, V.
    Munder, M.
    Mateos, M. V.
    Mark, T.
    Qi, M.
    Schecter, J.
    Amin, H.
    Qin, X.
    Deraedt, W.
    Ahmadi, T.
    Spencer, A.
    Sonneveld, P.
    HAEMATOLOGICA, 2016, 101 : 340 - 341
  • [7] Depth of Response and MRD with Daratumumab Plus Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM: CASTOR
    Spencer, Andrew
    Mark, Tomer
    Spicka, Ivan
    Masszi, Tamas
    Lauri, Birgitta
    Levin, Mark-David
    Bosi, Alberto
    Hungria, Vania
    Cavo, Michele
    Lee, Je-Jung
    Soong, David
    Casneuf, Tineke
    Chiu, Christopher
    Qin, Xiang
    Deraedt, William
    Qi, Ming
    Sasser, Kate
    Schecter, Jordan
    Weisel, Katja
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E85 - E85
  • [8] Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor
    Lentzsch, Suzanne
    Quach, Hang
    Chanan-Khan, Asher A.
    Horvath, Noemi
    Capra, Marcelo
    Ovilla, Roberto
    Jo, Jae-Cheol
    Shin, Ho-Jin
    Thiyagarajah, Piruntha
    Amin, Himal
    Casneuf, Tineke
    Sonneveld, Pieter
    Schecter, Jordan
    Hungria, Vania T. M.
    BLOOD, 2017, 130
  • [9] Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM Based on Prior Lines and Treatment Exposure: CASTOR
    Lentzsch, Suzanne
    Nooka, Ajay
    Quach, Hang
    Lee, Cindy
    Barreto, Wolney
    Corradini, Paolo
    Min, Chang Ki
    Scott, Emma
    Chanan-Khan, Asher
    Horvath, Noemi
    Capra, Marcelo
    Beksac, Meral
    Ovilla, Roberto
    Jo, Jae-Cheol
    Shin, Ho-Jin
    Soong, David
    Casneuf, Tineke
    Chiu, Christopher
    Qin, Xiang
    Amin, Himal
    Sonneveld, Pieter
    Schecter, Jordan
    Sasser, Kate
    Qi, Ming
    Mateos, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E133 - E133
  • [10] EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
    Lonial, Sagar
    Quach, Hang
    Dimopoulos, Meletios A.
    Rodriguez-Otero, Paula
    Berdeja, Jesus G.
    Richardson, Paul G.
    Kyada, Margee
    Chu, Shuyu
    Chen, Min
    Abad, Patricia C.
    Morando, Juliane
    van de Donk, Niels W. C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345